Non-alcoholic fatty liver disease

Powell, Elizabeth E.; Wong, Vincent W. S.; Rinella, Mary E.

doi:10.1016/s0140-6736(20)32511-3

Cited by 1,468 publications

(1,326 citation statements)

References 141 publications

Supporting

Mentioning

1,073

Contrasting

Unclassified

Order By: Relevance

“…Over the past four decades, non-alcoholic fatty liver dis-ease (NAFLD) has become the most prevalent chronic liver disease worldwide, in line with the increased prevalence of the features of metabolic syndrome [11,12]. The association be-tween non-alcoholic fatty liver disease (NAFLD) and HCC was well established recently [13].…”

Section: Introductionmentioning

confidence: 99%

Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection

Lin

Wang

et al. 2021

JPM

View full text Add to dashboard Cite

Backgrounds and Aim: Metabolic-associated fatty liver dis-ease (MAFLD) is a novel term proposed in 2020 to avoid the exclusion of certain subpopulations, though the application of this term in the real world is very limited. Here, we aimed to evaluate the impact of MAFLD on hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative resection. Methods: Patients with chronic hepatitis B (CHB)-related HCC who received hepatectomy between January 2010 and December 2019 were consecutively selected. The association between histologically proven concurrent MAFLD and clinical outcomes were retrospectively analyzed. Results: Among the 812 eligible patients with CHB-related HCC, 369 (45.4%) were diagnosed with concurrent MAFLD. After a mean follow-up of 65 months, 303 patients (37.3%) developed HCC recurrence, 111 (13.7%) died, and 12 (1.5%) received liver transplantation. Although no differences in the incidences of HCC recurrence (HR: 0.902, 95% CI: 0.719–1.131, p = 0.370) and death or liver transplantation (HR: 0.743, 95% CI: 0.518–1.006, p = 0.107) were observed between patients with and without MAFLD in multivariate analysis, the patients with MAFLD tended to achieve better recurrent-free survival compared to patients without MAFLD. Notably, lean MAFLD (BMI < 23 kg/m2) was a relative risk factor for tumor recurrence (HR: 2.030, 95% CI: 1.117–3.690, p = 0.020) among patients with MAFLD. Conclusions: The overall prognosis in HBV-related early-stage HCC, in terms of HCC recurrence and death or liver transplantation, was not significantly different between patients with and without MAFLD. Among patients with MALFD, lean-MAFLD was a risk factor for HCC recurrence. Further studies are warranted to validate these results.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection

Lin

Wang

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…Metabolic syndrome, of which obesity is an important component has a bidirectional association with nonalcoholic fatty liver disease (NAFLD, recently re-named metabolic associated fatty liver disease (MAFLD), a clinical condition characterized by intra-hepatic fat excess with or without inflammation and fibrosis [ 32 ]. NAFLD has the potential of becoming progressive, leading to liver cirrhosis, and is associated with serious cardio-metabolic abnormalities including T2DM [ 33 ]…”

Section: Chronic Low-grade Inflammation Insulin Resistance and Obesity-related Nafldmentioning

confidence: 99%

Findings from Studies Are Congruent with Obesity Having a Viral Origin, but What about Obesity-Related NAFLD?

Tarantino

Citro

Cataldi

2021

Viruses

View full text Add to dashboard Cite

Infection has recently started receiving greater attention as an unusual causative/inducing factor of obesity. Indeed, the biological plausibility of infectobesity includes direct roles of some viruses to reprogram host metabolism toward a more lipogenic and adipogenic status. Furthermore, the probability that humans may exchange microbiota components (virome/virobiota) points out that the altered response of IFN and other cytokines, which surfaces as a central mechanism for adipogenesis and obesity-associated immune suppression, is due to the fact that gut microbiota uphold intrinsic IFN signaling. Last but not least, the adaptation of both host immune and metabolic system under persistent viral infections play a central role in these phenomena. We hereby discuss the possible link between adenovirus and obesity-related nonalcoholic fatty liver disease (NAFLD). The mechanisms of adenovirus-36 (Ad-36) involvement in hepatic steatosis/NAFLD consist in reducing leptin gene expression and insulin sensitivity, augmenting glucose uptake, activating the lipogenic and pro-inflammatory pathways in adipose tissue, and increasing the level of macrophage chemoattractant protein-1, all of these ultimately leading to chronic inflammation and altered lipid metabolism. Moreover, by reducing leptin expression and secretion Ad-36 may have in turn an obesogenic effect through increased food intake or decreased energy expenditure via altered fat metabolism. Finally, Ad-36 is involved in upregulation of cAMP, phosphatidylinositol 3-kinase, and p38 signaling pathways, downregulation of Wnt10b expression, increased expression of CCAAT/enhancer binding protein-beta, and peroxisome proliferator-activated receptor gamma 2 with consequential lipid accumulation.

show abstract

“…Nonalcoholic fatty liver disease (NAFLD), which encompasses a broad spectrum ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), constitutes a global nightmare, since it affects up to one-fourth of people worldwide, representing a major cause of cirrhosis and hepatocellular carcinoma. 1 Besides the fact that NAFLD is usually thought to be closely related to obesity, almost 40% of affected individuals are classified as nonobese and 20% as lean, all of whom consequently suffer from excessive morbidity and mortality as well. 2 NAFLD is interconnected with significant comorbidities, namely atherosclerotic cardiovascular disease (although it is still a controversial area of knowledge), chronic kidney disease, type 2 diabetes mellitus (T2DM), atrial fibrillation, and obstructive sleep apnea.…”

Section: Dimitrios Patoulias *mentioning

confidence: 99%

Serum Resistin as a Biomarker in Nonalcoholic Fatty Liver Disease: Is This a Road to be Taken?

Patoulias¹

2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease

Cited by 1,468 publications

References 141 publications

Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection

Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection

Findings from Studies Are Congruent with Obesity Having a Viral Origin, but What about Obesity-Related NAFLD?

Serum Resistin as a Biomarker in Nonalcoholic Fatty Liver Disease: Is This a Road to be Taken?

Contact Info

Product

Resources

About